Stay updated with breaking news from Prognostic Index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.
Questions remain on how best to diagnose and treat CNS involvement in high-risk groups
In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center presented phase 2 results for 25 patients with TP53 mutations.
Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.
Andre Goy, MD, discusses the agents that are currently available for the treatment of patients with relapsed/refractory mantle cell lymphoma, explains the prevalence of high-risk features in this population, and emphasizes the importance of enrolling patients into clinical trials to move the needle forward.